GNPXGenprex Inc
Mkt Cap
$9.65MVolume
452,797.0052W High
$149.5052W Low
$7.00PE Ratio
-0.09GNPX Fundamentals
Price
$9.51Prev Close
$9.16Open
$8.3850D MA
$11.32Beta
1.11Avg. Volume
367,498.88EPS (Annual)
-$266.95P/B
4.58Rev/Employee
$0.00Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market...
PR Newswire·3d ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...
PR Newswire·3d ago
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets...
PR Newswire·12d ago
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System PR...
PR Newswire·8mo ago
Genprex Provides Update on Diabetes Gene Therapy Program
Genprex Provides Update on Diabetes Gene Therapy Program Genprex Provides Update on Diabetes Gene Therapy Program PR Newswire AUSTIN, Texas, Feb. 18, 2025 Signs an Amended & Restated License...
PR Newswire·8mo ago
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer Genprex Collaborators Find NPRL2 Gene Therapy...
PR Newswire·8mo ago
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer Genprex Announces...
PR Newswire·9mo ago
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire AUSTIN, Texas, Jan. 6, 2025 AUSTIN...
PR Newswire·10mo ago
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung...
PR Newswire·10mo ago
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer Genprex Signs Exclusive License to Additional Gene Therapy...
PR Newswire·11mo ago